254 related articles for article (PubMed ID: 25582279)
1. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.
Karsdal MA; Byrjalsen I; Alexandersen P; Bihlet A; Andersen JR; Riis BJ; Bay-Jensen AC; Christiansen C;
Osteoarthritis Cartilage; 2015 Apr; 23(4):532-43. PubMed ID: 25582279
[TBL] [Abstract][Full Text] [Related]
2. OA phenotypes, rather than disease stage, drive structural progression--identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA.
Karsdal MA; Bihlet A; Byrjalsen I; Alexandersen P; Ladel C; Michaels M; Andersen JR; Riis BJ; Kraus V; Bay-Jensen AC; Christiansen C
Osteoarthritis Cartilage; 2015 Apr; 23(4):550-8. PubMed ID: 25576879
[TBL] [Abstract][Full Text] [Related]
3. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis--the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation.
Karsdal MA; Byrjalsen I; Bay-Jensen AC; Henriksen K; Riis BJ; Christiansen C
BMC Musculoskelet Disord; 2010 Jun; 11():125. PubMed ID: 20565725
[TBL] [Abstract][Full Text] [Related]
4. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study.
Karsdal MA; Byrjalsen I; Henriksen K; Riis BJ; Lau EM; Arnold M; Christiansen C
Osteoarthritis Cartilage; 2010 Feb; 18(2):150-9. PubMed ID: 19747581
[TBL] [Abstract][Full Text] [Related]
5. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis.
Manicourt DH; Azria M; Mindeholm L; Thonar EJ; Devogelaer JP
Arthritis Rheum; 2006 Oct; 54(10):3205-11. PubMed ID: 17009253
[TBL] [Abstract][Full Text] [Related]
6. A low cartilage formation and repair endotype predicts radiographic progression of symptomatic knee osteoarthritis.
Luo Y; Samuels J; Krasnokutsky S; Byrjalsen I; Kraus VB; He Y; Karsdal MA; Abramson SB; Attur M; Bay-Jensen AC
J Orthop Traumatol; 2021 Mar; 22(1):10. PubMed ID: 33687578
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
[TBL] [Abstract][Full Text] [Related]
8. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study.
Bingham CO; Buckland-Wright JC; Garnero P; Cohen SB; Dougados M; Adami S; Clauw DJ; Spector TD; Pelletier JP; Raynauld JP; Strand V; Simon LS; Meyer JM; Cline GA; Beary JF
Arthritis Rheum; 2006 Nov; 54(11):3494-507. PubMed ID: 17075851
[TBL] [Abstract][Full Text] [Related]
9. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis.
Bagger YZ; Tankó LB; Alexandersen P; Karsdal MA; Olson M; Mindeholm L; Azria M; Christiansen C
Bone; 2005 Sep; 37(3):425-30. PubMed ID: 16005273
[TBL] [Abstract][Full Text] [Related]
10. A 12-week randomized, double-blind, placebo-controlled multicenter study of choline-stabilized orthosilicic acid in patients with symptomatic knee osteoarthritis.
Geusens P; Pavelka K; Rovensky J; Vanhoof J; Demeester N; Calomme M; Vanden Berghe D
BMC Musculoskelet Disord; 2017 Jan; 18(1):2. PubMed ID: 28056936
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial evaluating transdermal Ibuprofen for moderate to severe knee osteoarthritis.
Varadi G; Zhu Z; Blattler T; Hosle M; Loher A; Pokorny R; Frey D; Carter SG
Pain Physician; 2013; 16(6):E749-62. PubMed ID: 24284856
[TBL] [Abstract][Full Text] [Related]
12. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial.
Garnero P; Aronstein WS; Cohen SB; Conaghan PG; Cline GA; Christiansen C; Beary JF; Meyer JM; Bingham CO
Osteoarthritis Cartilage; 2008 Jun; 16(6):660-6. PubMed ID: 17993283
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial.
Cooper C; Reginster JY; Chapurlat R; Christiansen C; Genant H; Bellamy N; Bensen W; Navarro F; Badurski J; Nasonov E; Chevalier X; Sambrook PN
Curr Med Res Opin; 2012 Feb; 28(2):231-9. PubMed ID: 22148897
[TBL] [Abstract][Full Text] [Related]
14. Effects of single or combined administration of salmon calcitonin and omega-3 fatty acids vs. diclofenac sodium in sodium monoiodoacetate-induced knee osteoarthritis in male Wistar rats.
Adeyemi WJ; Olayaki LA
J Basic Clin Physiol Pharmacol; 2017 Nov; 28(6):573-582. PubMed ID: 28917083
[TBL] [Abstract][Full Text] [Related]
15. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo.
Uebelhart D; Malaise M; Marcolongo R; de Vathaire F; Piperno M; Mailleux E; Fioravanti A; Matoso L; Vignon E
Osteoarthritis Cartilage; 2004 Apr; 12(4):269-76. PubMed ID: 15023378
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of E-OA-07 in moderate to severe symptoms of osteoarthritis: a double-blind randomized placebo-controlled study.
Kulkarni MP; Shakeel A; Shinde BS; Rosenbloom RA
Am J Ther; 2011; 18(2):170-7. PubMed ID: 21317618
[TBL] [Abstract][Full Text] [Related]
17. A prospective, randomized, double-blind, placebo controlled study to evaluate the efficacy of intraarticular hyaluronic acid for osteoarthritis of the knee.
Petrella RJ; Petrella M
J Rheumatol; 2006 May; 33(5):951-6. PubMed ID: 16652426
[TBL] [Abstract][Full Text] [Related]
18. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
Kivitz A; Ma C; Ahdieh H; Galer BS
Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study.
Lugo JP; Saiyed ZM; Lane NE
Nutr J; 2016 Jan; 15():14. PubMed ID: 26822714
[TBL] [Abstract][Full Text] [Related]
20. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial.
Lohmander LS; Hellot S; Dreher D; Krantz EF; Kruger DS; Guermazi A; Eckstein F
Arthritis Rheumatol; 2014 Jul; 66(7):1820-31. PubMed ID: 24740822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
